cas 700-49-2|| where to buy 2-fluoro-9H-purin-6-amine

Product Name:2-fluoro-9H-purin-6-amine

IUPAC Name:2-fluoro-9H-purin-6-amine

Packing Unit	Available Stock	Price($)
CM112176-5g	in stock	Ǌǜ
CM112176-10g	in stock	ȺũȬ
CM112176-25g	in stock	ǜƦȺ

For R&D use only.

Inquiry Form

Chemical Name

CAS Number

Quantity*

Required Specifications*
(Assay %, Material Grade etc.)

Contact Name*

Contact Email*

Additional Notes

Verification code*

refresh

: CAS NO:700-49-2; Molecular Formula:C5H4FN5; Melting Point:-; Smiles Code:NC1=C2N=CNC2=NC(F)=N1; Density:

: Catalog Number:CM112176; Molecular Weight:153.12; Boiling Point:676.9°C at 760 mmHg; MDL No:MFCD01632749; Storage:Keep in a tight container and store at ambient temperature

: Purines; Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.; purine wholesale; Find trusted purine wholesaler. Any requirements and problems can ask us at any time.

: Islatravir and Lenacapavir; Gilead and Merck announced results from the Phase 2 clinical study evaluating the investigational combination of islatravir, an investigational nucleoside reverse transcriptase translocation inhibitor, and lenacapavir, a first-in-class , long-acting HIV capsid inhibitor. At 24 weeks, the novel investigational combination maintained a high rate (94.2%) of viral suppression (HIV-1 RNA <50 copies/mL), which is a secondary endpoint of the study. Results of the primary endpoint (HIV-1 RNA ≥50 copies/mL (c/mL) showed that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of >50 copies/mL at Week 24;the participant later suppressed on islatravir and lenacapavir at Week 30.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.